IART Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
I would not buy Integra LifeSciences right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock is sitting near support in pre-market, but the overall setup is weak: price trend is flat-to-bearish, recent analyst actions are mostly negative, quarterly fundamentals are deteriorating, and there is no strong bullish catalyst from options, news, insiders, hedge funds, or congressional trading. For an impatient investor, this is not a strong immediate buy. Best call: hold and wait for clearer execution improvement or a better entry after earnings.
IART is trading pre-market at 10.54, just below the pivot at 10.72 and above first support at 10.151. RSI_6 at 51.13 is neutral, so momentum is not strong either way. The MACD histogram is negative and expanding, which points to weakening short-term momentum. Moving averages are converging, suggesting a lack of trend conviction. Overall, the technical picture is neutral-to-bearish, with risk of revisiting support unless buyers reclaim 10.72 and then 11.29 resistance.
["Wells Fargo noted revenue could build sequentially through 2026, implying a back-half-loaded setup.", "Braintree becoming operational by June is viewed as a potential second-half catalyst.", "Underlying demand still exists for regenerative tissue and specialty surgery products."]
["No news in the recent week, so there is no fresh positive event-driven catalyst.", "Q4 2025 revenue fell 1.74% YoY and profitability weakened sharply, with net income and EPS both declining to slightly negative levels.", "Gross margin compressed to 57.02%, down 3.71% YoY.", "Analyst sentiment has worsened: Truist lowered its target and kept Hold, Argus downgraded to Hold, Citi kept Sell, and JPMorgan kept Underweight.", "The company continues to face execution issues and manufacturing quality-control overhangs.", "Hedge funds and insiders are both neutral with no meaningful buying trend.", "No recent congress trading data is available.", "Pattern-based trend data suggests downside over the next day and week."]
Latest reported quarter: 2025/Q4. Revenue was $434.9M, down 1.74% YoY, showing weak top-line growth. Net income was -$1.7M versus prior-year profitability, and EPS was -$0.02, both materially worse YoY. Gross margin declined to 57.02%, down 3.71 points YoY. This points to slowing growth and margin pressure rather than a healthy expansion phase.
Recent analyst trend is negative. Truist lowered the price target to $12 from $13 and maintained Hold, arguing the stock deserves a discount due to execution issues and weaker growth/margin profile. Argus downgraded the stock to Hold from Buy because of inconsistent operating performance and quality-control problems. Wells Fargo is Equal Weight with a $12 target, suggesting neutrality. Citi is Sell with a $9 target, and JPMorgan is Underweight with an $11 target. Wall Street is broadly cautious, with more cons than pros until execution improves.
